Diligence memo · auto-generated · as of July 3, 2026
Theranos Inc
Theranos Inc has raised $627M over 2 rounds; too few niche peers to rank its valuation yet.
Businessfiled
Theranos Inc operates in Biotechnology, based in PALO ALTO.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Theranos Inc has raised $627M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Growth/Late (a round over $400M).
Largest single filing: $582M on 2017-05-15.
Most recent recorded round closed around 2017-05-15.
Valuation (modeled)modeled
Provath models Theranos Inc at approximately $24.7B (range $3.6B–$44.5B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Too few comparable companies in this niche to rank the valuation fairly yet.
Financing rhythm & timingmixed
Historic cadence: a new round about every 82 months.
Last raise 9.1 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 12.9× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 100% of Biotechnology peers (4293 compared).
Modeled value ranks above 100% of those peers.
Closest niche peers: Moderna Therapeutics, Inc., Allogene Therapeutics, Inc., Juno Therapeutics, Inc..
Peoplefiled
10 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.